Lenvima (lenvatinib) / Eisai, Merck (MSD) 
Welcome,         Profile    Billing    Logout  
 53 Diseases   490 Trials   490 Trials   8927 News 


«12...8990919293949596979899...123124»
  • ||||||||||  Avastin (bevacizumab) / Roche, Opdivo (nivolumab) / Ono Pharma, BMS, Cabometyx (cabozantinib tablet) / Takeda, Exelixis, Ipsen
    Retrospective data, Review, Journal:  Systemic Therapy and Sequencing Options in Advanced Hepatocellular Carcinoma: A Systematic Review and Network Meta-analysis. (Pubmed Central) -  Feb 12, 2021   
    Network meta-analysis showed the combination of atezolizumab and bevacizumab was superior in patients with HCC treated in the first-line setting compared with lenvatinib (HR, 0.63; 95% CI, 0.44-0.89), sorafenib (HR, 0.58; 95% CI, 0.42-0.80), and nivolumab (HR, 0.68; 95% CI, 0.48-0.98)...Regorafenib and cabozantinib are preferred options in refractory patients, with ramucirumab as an additional option in those with levels of AFP of 400 ng/mL or higher. Future trials should focus on other potential combinations and best treatment strategy in patients with prior VEGFi/CPI exposure.
  • ||||||||||  Opdivo (nivolumab) / BMS, Lenvima (lenvatinib) / Eisai, Merck (MSD)
    Trial completion date, Trial primary completion date:  IMMUNIB: Immunotherapy With Nivolumab in Combination With Lenvatinib for Advanced Stage Hepatocellular Carcinoma (clinicaltrials.gov) -  Feb 12, 2021   
    P2,  N=50, Recruiting, 
    Future trials should focus on other potential combinations and best treatment strategy in patients with prior VEGFi/CPI exposure. Trial completion date: Oct 2021 --> May 2022 | Trial primary completion date: Jul 2021 --> Feb 2022
  • ||||||||||  Clinical, Journal:  Tyrosine kinase inhibitor-induced hypertension-marker of anti-tumour treatment efficacy or cardiovascular risk factor? (Pubmed Central) -  Feb 11, 2021   
    report the incidence of treatment-related hypertension in patients treated with lenvatinib, a newer TKI, for non-resectable hepatocellular carcinoma...These findings contribute to a better understanding of TKI-associated hypertension and help in choosing the most appropriate antihypertensive agents in this setting. Active control of hypertension may help more patients benefit from longer TKI therapy, possibly resulting in better cancer outcomes.
  • ||||||||||  lenvatinib / Generic mfg.
    Journal:  Changes in blood pressure during treatment with the tyrosine kinase inhibitor lenvatinib. (Pubmed Central) -  Feb 11, 2021   
    Furthermore, patients with fluid retention had significantly higher BP or required more intensive BP treatment compared with those without fluid retention. Lenvatinib might lead to HT without fluid retention soon after the initiation of treatment, subsequently leading to a reduction in urinary sodium excretion, thereby contributing to a rise in BP by fluid retention.
  • ||||||||||  Lenvima (lenvatinib) / Eisai, Merck (MSD)
    Trial completion date, Trial initiation date, Trial primary completion date, Checkpoint inhibition:  Safety and Efficacy of Lenvatinib in Subjects With HCC Progression After First Line Treatment With Checkpoint Inhibitors (clinicaltrials.gov) -  Feb 10, 2021   
    P=N/A,  N=20, Not yet recruiting, 
    Lenvatinib might lead to HT without fluid retention soon after the initiation of treatment, subsequently leading to a reduction in urinary sodium excretion, thereby contributing to a rise in BP by fluid retention. Trial completion date: Feb 2021 --> Feb 2023 | Initiation date: Jul 2020 --> Jul 2022 | Trial primary completion date: Dec 2020 --> Dec 2022
  • ||||||||||  Avastin (bevacizumab) / Roche, Cabometyx (cabozantinib tablet) / Takeda, Exelixis, Ipsen
    Clinical, Review, Journal:  Sequencing of systemic treatment for hepatocellular carcinoma: Second line competitors. (Pubmed Central) -  Feb 9, 2021   
    Other TKIs for second line treatment include cabozantinib and ramucirumab (specifically for patients with Alpha-fetoprotein values ≥ 400 ng/mL). The combination of TKIs with immunotherapy may represent a big step forward for these patients in the near future.
  • ||||||||||  Nexavar (sorafenib) / Bayer, Amgen
    Journal, HEOR:  Lenvatinib versus sorafenib for unresectable hepatocellular carcinoma: a cost-effectiveness analysis. (Pubmed Central) -  Feb 9, 2021   
    Lenvatinib treatment resulted in 2.916 QALYs for patients weighing <60 and ≥60 kg at a cost of $57,049.43 and $75,900.36, The incremental cost-effectiveness ratio to the sorafenib treatment group was $11,825.94/QALY and $28,627.12/QALY, respectively. According to WHO's triple GDP per capita, the use of lenvatinib by providing drugs is a cost-effective strategy.
  • ||||||||||  Keytruda (pembrolizumab) / Merck (MSD), Lenvima (lenvatinib) / Eisai, Merck (MSD)
    Trial initiation date, Tumor mutational burden, Metastases:  Pembrolizumab in Combination With Lenvatinib in Patients With Advanced Biliary Tract Carcinoma (clinicaltrials.gov) -  Feb 7, 2021   
    P2,  N=40, Not yet recruiting, 
    According to WHO's triple GDP per capita, the use of lenvatinib by providing drugs is a cost-effective strategy. Initiation date: Nov 2020 --> Apr 2021
  • ||||||||||  Cabometyx (cabozantinib tablet) / Takeda, Exelixis, Ipsen
    Clinical, Review, Journal:  Clinical use of vascular endothelial growth factor receptor inhibitors for the treatment of renal cell carcinoma. (Pubmed Central) -  Feb 5, 2021   
    Six small molecules that inhibit VEGFR1/2/3, namely, sunitinib, sorafenib, axitinib, pazopanib, cabozantinib, and lenvatinib, have been approved by the Food and Drug Administration (FDA) for the treatment of RCC...To some extent, these drugs improve quality of life and prolong the survival of patients. This paper presents a review of the systemic targeted therapies against VEGFRs that have been approved so far or are undergoing trials as treatments for RCC.
  • ||||||||||  Cabometyx (cabozantinib tablet) / Takeda, Exelixis, Ipsen
    Journal:  Molecular Modelling Studies on Pyrazole Derivatives for the Design of Potent Rearranged during Transfection Kinase Inhibitors. (Pubmed Central) -  Feb 3, 2021   
    A number of RET kinase inhibitors have been approved by the FDA for the treatment of cancer, such as cabozantinib, vandetanib, lenvatinib, and sorafenib...Therefore, we have designed ten RET kinase inhibitors, which showed higher inhibitory activity than the most active compound of the series. The results of our study provide insights to design more potent and selective RET kinase inhibitors.
  • ||||||||||  thyroxine / Generic mfg., lenvatinib / Generic mfg.
    [VIRTUAL] Brain Metastases in a Patient With Papillary Thyroid Carcinoma. Clinical Case Report (On-Demand) -  Feb 2, 2021 - Abstract #ENDO2021ENDO_1896;    
    We started by suppressing TSH with levothyroxine...Patient received management with gamma Knife radiosurgery for BM and with lenvatinib 24mg day...For oral presentations, the abstracts are embargoed until the session begins. The Endocrine Society reserves the right to lift the embargo on specific abstracts that are selected for promotion prior to or during ENDO 2021.
  • ||||||||||  Tafinlar (dabrafenib) / Novartis
    [VIRTUAL] Dabrafenib Induced Pancreatitis: A Rare Event During RAI- Refractory Treatment of Metastatic Papillary Thyroid Cancer (On-Demand) -  Feb 2, 2021 - Abstract #ENDO2021ENDO_1875;    
    Dabrafenib, a BRAF selective tyrosine kinase inhibitor (TKI) has been associated with pancreatitis alone, and in combination with trametinib (a MEK pathway inhibitor)...At present patient is tolerating Lenvatinib therapy...For oral presentations, the abstracts are embargoed until the session begins. The Endocrine Society reserves the right to lift the embargo on specific abstracts that are selected for promotion prior to or during ENDO 2021.
  • ||||||||||  lenvatinib / Generic mfg.
    ICI+Lenvatinib (Twitter) -  Feb 1, 2021   
  • ||||||||||  Caprelsa (vandetanib) / Sanofi
    Journal:  Passive Diffusion vs Active pH-Dependent Encapsulation of Tyrosine Kinase Inhibitors Vandetanib and Lenvatinib into Folate-Targeted Ferritin Delivery System. (Pubmed Central) -  Jan 30, 2021   
    Importantly, the long-term cytotoxic experiments revealed that compared to the pH-dependent encapsulation, the passively-loaded TKIs exert markedly higher anticancer activity, most likely due to undesired influence of harsh acidic environment used for the pH-dependent encapsulation on the TKIs' structural and functional properties. Since the passive loading does not require a reassembly step for which acids are needed, the presented investigation serves as a solid basis for future studies focused on encapsulation of small hydrophobic molecules.
  • ||||||||||  Keytruda (pembrolizumab) / Merck (MSD)
    [VIRTUAL] 10191: Scientific Plenary I: Innovation and Progress in Gynecologic Oncology () -  Jan 29, 2021 - Abstract #SGO2021SGO_619;    
    Learning Objective 4: Analyze the activity of pembrolizumab and lenvatinib in advanced endometrial cancer 5. Learning Objective 5: Describe the incidence and characteristics of bullying, discrimination and microagressions directed towards women gynecologic oncologists.